Objective: The aims of this study were to investigate the effect of ascorbic acid (AA) supplementation on the oxidisability of low density lipoprotein (LDL) in vitro and on plasma lipoproteins under controlled dietary conditions. Design: Randomised single-blind cross-over trial. Setting: Free living subjects. Subjects: Eight male smokers (age: 25 AE 2.4 y, BMI: 20.7 AE 0.5, cigarettes per day: 19.1 AE 2.4; means AE s.e.). Interventions: Dietary intake was determined and all subjects were advised to achieve an intake as close as possible to the recommended dietary intake of AA (40 mg). After two weeks on the baseline diet, subjects were asked to consume 1 g AA per day for two weeks followed by two weeks of placebo supplementation, or vice versa. In view of the carry-over effects of plasma AA, a wash-out period was incorporated between treatments. Duplicate venous blood samples were collected before and after supplementation and the plasma concentrations of AA, lipids and lipoproteins were determined. The in vitro copper-induced oxidisability of LDL was assessed by monitoring of the absorbance of 234 nm. Results: No changes in the plasma lipids or the oxidisability of LDL were found after AA supplementation compared to placebo. Plasma AA concentrations doubled on average after supplementation indicating that the lack of effect was not a result of poor compliance. Conclusions: AA supplementation at this dose did not alter plasma lipids of LDL oxidisability in male smokers.
Introduction
Epidemiological evidence is suggestive of a protective role for ascorbic acid (AA) against coronary heart disease (CHD). The protective effects have been attributed to the antioxidant properties of AA (Gey, 1995) , as well as its relationship with plasma lipids (Hemila, 1992) . Several studies have reported a positive correlation between plasma or dietary AA and high density lipoprotein-cholesterol (HDL-C) concentrations (Bates et al, 1977; Burr et al, 1982; Dallal et al, 1989; Itoh et al, 1990; Jacques, 1992; Bazzarre et al, 1992; Hallfrisch et al, 1994; Jacques et al, 1994) and a negative correlation with plasma total cholesterol (Burr et al, 1982; Greco et al, 1982; Simon et al, 1993) . Although not all studies have supported these associations with lipids (Elwood et al, 1970; Salonen et al, 1988) , the balance of epidemiological evidence is consistent with the notion that AA is protective against CHD.
The observations made by Steinberg et al (1989) provided the basis of the oxidation theory of atherogenesis. Oxidatively modi®ed LDL is taken up ef®ciently by scavenger receptors and subsequently in¯uences monocyte and macrophage motility. Macrophages which take up the oxidatively modi®ed LDL become cholesterol-laden foam cells which lead to the development of the fatty streak, the earliest detectable sign of an atheroma. Hence the potential role of antioxidants in the prevention of such a process has been the subject of much attention. Since some antioxidants, such as AA and vitamin E, reduce the oxidative modi®cation of LDL in vitro (Sato et al, 1990; Jialal et al, 1990; Esterbauer et al, 1991; Retsky et al, 1993) it is possible that the risk of atherogenesis is increased in subjects with low plasma antioxidant levels, such as smokers. Lower plasma AA concentrations have been observed in smokers relative to non-smokers (Elwood et al, 1970; Schectman, 1993; Duthie et al, 1993; BoltonSmith, 1993; Mezzetti et al, 1995) and smoking cessation results in increased plasma AA concentrations (Brown, 1996) . Although the lower AA levels could be due to smokers consuming fewer servings of fruit and vegetables compared to non-smokers (Schectman, 1993; BoltonSmith, 1993) , exposure of plasma to ®ltered cigarette smoke showed a dramatic decrease in AA concentrations (Frei et al, 1991) . It has been calculated that an average puff of cigarette smoke causes oxidation of about 0.09 mg of AA (Cross & Halliwell, 1993) which is a signi®cant proportion of the recommended daily intake (RDI) of 40 mg AA per day (Read, 1990) for men who smoke two packets of cigarettes per day.
Supplementation trials have been carried out to test the epidemiological association between AA and plasma lipids. The results of some trials re¯ected the epidemiological observations (Samuel & Shalchi, 1964; Spittle, 1971; Gatto et al, 1996; Fidanza et al, 1982; Ginter, 1979) while others showed no effect despite a wide range in the amounts (0.2± 6 g/d) of the supplements which were consumed (Samuel & Shalchi, 1964; Spittle, 1971; Buzzard et al, 1982; Aro et al, 1988; Burr et al, 1985; Crawford et al, 1975; Wahlberg & Walldius, 1982; Khan & Seedarnee, 1981; Johnson & Obenshain, 1981; Menne et al, 1975; Peterson et al, 1995) . However, the quality of the trials has been variable (Hemila, 1992) and some trials have suffered from the lack of a control group, poor dietary control, no evidence of compliance, a heterogeneous population with respect to pathological conditions and AA status, and the use of elderly subjects who have a recognised age-related alteration in the metabolism of AA. Similarly, studies aimed at testing the effect of dietary/supplemental AA per se on LDL oxidation are inconclusive (Belcher et al, 1993; Harats et al, 1990; Fuller et al, 1995; Ri®ci & Khachadurian, 1993) . The aim of this study was to investigate the effect of AA supplementation on plasma lipids and the in vitro oxidisability of LDL in male smokers, a group of subjects who have a recognised increased requirement for AA (Cross & Halliwell, 1993) , as well as disturbed lipoprotein metabolism (Craig et al, 1989) . In order to accentuate the effect (if any), the subjects' AA intake was reduced prior to supplementation.
Materials and methods

Subjects and study design
Ten adult males were recruited through advertisements placed in or near the University of Sydney. In order to be entered in the study, subjects had to be regular smokers, not taking any medication or nutritional supplements, not on any special diet, not suffering from any disorders that may affect lipid metabolism and not to have gained or lost more than 2 kg over the past year. Potential volunteers were screened (by questionnaire) for lactose intolerance as the placebo tablets consisted of lactose. The study was approved by the Human Ethics Committee of the University of Sydney and written consent was obtained from each volunteer prior to the commencement of the trial.
Eight subjects successfully completed the study (Table  1) , with two individuals withdrawing due to illness. Smoking was not encouraged by this study and at the conclusion of the trial smoking cessation kits (The NSW QUIT Campaign, Code QLE.11) were provided to all volunteers.
The study was a single-blind cross-over trial of 53 d duration, it consisted of four main periods:
1. Pre-trial dietary modi®cation (days 1±14): The aim of this period was to familiarise the volunteers with the diet which they were asked to maintain for the duration of the study. All subjects were asked to modify their diet in order to achieve an intake of AA as close as possible to 40 mg/d, the recommended dietary intake (RDI) for men (Read, 1990) . A blood sample was collected on day 1 together with a diet history and a second blood sample was collected on day 12 to obtain a biochemical measure of the change in AA intake. 2. Supplementation period 1 (days 14±28): Following the collection of a blood sample on day 14, individuals were randomly allocated to supplementation with either AA or placebo. The AA supplement consisted of two 500 mg tablets while the placebo tablets were physically identical but consisted mainly of lactose. Both the AA and the placebo tablets were formulated under controlled conditions by the Department of Pharmacy, University of Sydney. The volunteers were instructed to consume one tablet with the morning meal and the second with the evening meal. In order to minimise the biological variation in the measurement of plasma cholesterol (Samman, 1991) , duplicate blood samples were taken 2±4 d apart. 3. Wash-out period (days 28±37): Because of the previously reported carry-over effect of AA supplementation (Gatto et al, 1996) , a wash-out period was introduced. 4. Supplementation period 2 (days 37±53): During this part of the study the two groups crossed-over with respect to the supplementation. Those originally allocated to AA were switched to Placebo supplementation and vice versa. As for the Period 1, duplicate blood samples were collected (days 51 and 53).
Nutrient intake analysis
Dietary information was obtained with a diet history interview prior to commencement of the study. The intake of Vitamin C was measured before and estimated after dietary modi®cations were instructed. Following the 14 d of the pre-trial period, the subjects were requested to complete a Food Frequency Questionnaire to determine their habitual nutrient intake. Dietary intake data were obtained using the DIET 1 software (Xyris Software Pty Lt, Qld; 1992) and the NUTTAB Data Base of Australian foods.
Assessment of compliance
Compliance was estimated by pill count where AA and placebo tablets were provided in two weekly batches with a known number of surplus tablets. The volunteers were asked to return any remaining tablets so as to monitor apparent consumption. Plasma AA concentrations also acted as an indicator of compliance for both dietary modi®cation and the supplementation periods.
Blood collection and preparation
Nine blood samples (40 mL) were collected from the volunteers over a 53 d period. Subjects were asked to be in the fasted state (10±12 h) and to rest in a supine position for 5±10 min before blood sampling. Venous blood was collected from the antecubital vein using a winged infusion set and plastic syringe (Terumo Med. Corp., MD, USA).
Blood for the analysis of plasma lipids was collected in tubes containing disodium EDTA (0.01%) while the blood taken for the determination of the plasma AA concentration and fatty acid pro®le was collected into heparinised tubes (125 IU heparin; Disposable Products Pty Ltd, South Australia). Immediately following the collection of blood samples, the tubes were placed in ice and within 90 min, the plasma was separated by centrifugation at 1000 g for 10 min at 4 C then stored at 780 C. Samples targeted for AA analysis were processed immediately as described below.
Ascorbic acid analysis Analysis of AA was carried by high performance liquid chromatography (HPLC) with UV detection as described previously (Gatto et al, 1996) . Brie¯y, 1 mL plasma was mixed with 1 mL of metaphosphoric acid (25% w/v) and 3 mL water (Milli-Q). The samples were then centrifuged at 1000 g for 10 min at 4 C, the supernatant was ®ltered through a 0.45 mm ®lter (ACTIVON, Scienti®c Products Company Pty Ltd, NSW, Australia) and 25 mL of the ®ltrate was injected through a C18 reverse phase column (Spherisorb ODS 4.6 6 25 cm, 5 mm particle size) together with a C18 guard column. Samples were kept on ice and protected from light and compared with standards prepared with L-ascorbic acid (Fisons Scienti®c Equipment, England).
Lipid analysis
The concentrations of plasma total cholesterol (Boehringer Mannheim, Australia) and triacylglycerol (TAG) (triacylglycerol-PAP Ultimate 5, Roche products, Australia) were measured enzymatically using an auto analyser (Cobas Fara II; Roche Diagnostica, Switzerland). Total HDL-cholesterol and HDL 3 -cholesterol concentrations were assayed from the supernatant after precipitation with dextran sulphate and magnesium chloride as described by Warnick et al (1982) . HDL 2 -cholesterol was estimated by difference while LDL-cholesterol was determined using the SI version (Samman & Truswell, 1993) of the Friedewald equation.
Plasma fatty acids were transesteri®ed (Lepage & Roy, 1986 ) then analysed using capillary gas chromatograph (model 5890A, Hewlett Packard, North Ryde) with¯ame ionisation detection.
LDL isolation
Plasma LDL was isolated using a single spin ultracentrifugation procedure (Gatto & Samman, 1995) . Brie¯y, plasma was adjusted to density (d) 1.21 kg/L then layered under saline solution (d 1.006 kg/L; containing 0.01% EDTA) and centrifuged at 450 000 g for 3.5 h at 4 C. LDL was removed by aspiration then eluted through a desalting column (Econo-Pac 10DG, BIO-RAD Laboratories, Hercules, CA) with 10 mmol/L phosphate-buffered saline (PBS). The concentration of protein in the isolated LDL was determined using a modi®ed Lowry method (Markwell et al, 1978) .
In vitro LDL oxidation Oxidation of LDL was determined as the production of conjugated dienes by the measurement of absorbance at 234 nm (Esterbauer et al, 1989) at 5 min intervals. Oxidation was carried out by incubating 200 mg LDL protein with CuSO 4 (5 mmol/L) for 1.5 h at 37 C in a spectrophotometer (UV-160A with CPS-Controller, Shimadsu Corporation, Japan).
Statistical analyses
Two tailed paired t-tests were performed using Statview (Abacus Concepts Inc., CA) and correlations were made using Cricket Graph (Cricket Software, PA). Statistical signi®cance was taken at P`0.05. All data are presented as means AE s.e.m.
Results
The mean dietary intake of AA on entry to the study was estimated to be 170.5 AE 32.7 mg/d (Table 2 ) and after dietary modi®cation the intake was reduced to 59.4 AE 0.8 mg/d. Consistent with the mean reduction in dietary AA intake, the plasma AA concentration fell signi®cantly (P 0.05) by 16.6 AE 9.6 mM. Despite the concurrent reduction in the average intake and average plasma AA concentrations, there was no signi®cant correlation between the two parameters. Upon supplementation, the plasma AA concentration increased signi®cantly from 54.4 AE 7.0 to 111.2 AE 13.1 mM while it remained relatively constant during the placebo period. These effects on plasma AA are supported by the apparent compliance of the volunteers with supplementation as determined by pill count. From the number of tablets returned, it was estimated that 83.3 AE 8.3% of AA supplements were consumed. No side effects were reported by any of the volunteers.
There were no signi®cant changes in the concentrations of the plasma total cholesterol or TAG or the distribution of cholesterol among the lipoprotein subfractions after AA supplementation as compared with placebo (Table 3) . Similarly the oxidisability of LDL in vitro, as determined by the lag phase, the extent and rate of lipid peroxidation, was unaffected by AA supplementation (Table 4) . As the oxidisability of LDL depends on the amount of unsaturated fatty acids which act as substrates for oxidation, the fatty acid pro®les were measured and these were unaffected by AA supplementation (Table 3) .
Discussion
The subjects in this study complied with both the dietary modi®cation which was prescribed and the supplementation regimen as evidenced by the responses of the plasma AA concentrations during those periods. The plasma AA concentration decreased after dietary counselling corresponding with a lower intake of AA, whereas it increased after AA supplementation. Following supplementations, plasma AA levels doubled from baseline values (from 54.4 AE 7.0 to 111.2 AE 13.1 mmol/L) despite the continuation of smoking. This is very similar to the peak values obtained in healthy women (non-smokers) who were supplemented with a similar dose of AA (Gatto et al, 1996) . This supports the notion that plasma AA levels begin to plateau at a concentration of approximately 80 mmol/L (Gershoff, 1993) , however, the exact threshold concentration will depend on the method of measurement and the individual variation for plasma AA (Lux & Naidoo, 1994) .
There has been con¯icting reports regarding the effect of AA on plasma lipids with some studies observing a more desirable lipid and lipoprotein pro®le with supplementation (1992) . In order to maximise the effect (if any) of AA on plasma lipids, smokers were recruited and provided advice on maintaining a low AA diet followed by supplementation. In addition, blood sampling was carried out in duplicate in order to reduce the intraindividual variability in the cholesterol measurement (Samman, 1991) . In spite of these measures, the plasma lipids and the distribution of cholesterol among the lipoprotein fractions were remarkably unaffected by AA. A similar lack of effect had been observed in female smokers (Elwood et al, 1970) but not non-smokers (Gatto et al, 1996) . In the latter study, AA resulted in a 16% reduction in LDL-cholesterol after four weeks of supplementation however, because of a carry-over effect of plasma AA into the placebo period following supplementation, the trial was analysed as an uncontrolled, paired study. It has been suggested (Ginter, 1979 ) that the hypocholesterolaemic effect of AA depends on the initial plasma cholesterol concentrations as well as the individuals' AA status. Plasma cholesterol levels within the normal range (`5.2 mmol/L) are less likely to be affected by AA supplementation while in hypercholesterolaemic subjects with a concurrent low vitamin C intake, the cholesterollowering effect of AA may be more obvious. The lack of effect of AA in this study may be related to the low plasma cholesterol concentration of the volunteers and the relatively high AA status despite a reduction in AA intake during the Pre-Trial Period.
AA is reported to affect lipoprotein metabolism in different ways (Hemila, 1992) . AA may increase the number of LDL receptors in cultured cells (Aulinskas et al, 1983) while AA de®ciency results in reduced bile acid synthesis due to a reduction in the activity of cholesterol 7a-hydroxylase, the rate limiting enzyme in bile acid synthesis (Holloway et al, 1981) . In transgenic rats who are unable to synthesise AA, there is a reduction in the expression and subsequent plasma concentration of apolipoprotein A-I (Horio et al, 1993) . That these effects occur in humans who consume an adequate amount of AA remains to be determined. However, this study does not provide any supportive evidence in this regard.
The oxidisability of LDL ex vivo was unaffected by supplementation with AA which agrees with a previous report (Belcher et al, 1993) but not others (Harats et al, 1990; Fuller et al, 1995; Ri®ci & Khachadurian, 1993) . The plasma fatty acids pro®le was not different between the supplementation and placebo periods which suggests that the subjects had maintained a constant intake with respect to at least those nutrients which have a signi®cant impact on oxidisability. In contrast to these ®ndings, in a study by Harats et al (1990) , AA supplementation (1 g/d for two weeks) reduced the oxidative damage to LDL in response to acute cigarette smoking as determined by a reduced rate of production of thiobarbituric acid reactive substances (TBARS) and lower uptake of LDL by macrophages. In a small number of healthy non-smokers, it was demonstrated that AA reduces the extent of oxidation of apolipoprotein B containing lipoproteins (d`1.063 g/ml, not speci®cally LDL) (Ri®ci & Khachadurian, 1993) . More recently, Fuller et al (1995) reported the results of a study similar to this study with the exception of the design being parallel rather than a cross-over where it was shown that AA supplements reduce the copper catalysed oxidisability of LDL in smokers.
The lack of effect in this study and that of Belcher et al (1993) may be related to the duration of the experimental period being only two weeks. However, the plasma concentration of AA in this study (111.2 AE 13.1 mmol/L) was similar to that reported by Fuller et al (1995) at four weeks (127.2 AE 37.6 mmol/L) which suggests the lack of effect was unrelated to the plasma AA concentration. It is noteworthy that the plasma AA concentration after four weeks was lower than that reported at two weeks (Fuller et al, 1995) which corroborate our previous observation (Gatto et al, 1996) suggesting a renal threshold effect and explains, in part, the lack of correlation between AA intake and its plasma concentration.
An alternative explanation for the discrepancy between this study and that of Fuller et al (1995) may lie in other aspects of the study such as the methodology used for the determination of LDL oxidation and the experimental design. This study compared the oxidisability of LDL of the same subjects during supplementation with AA or placebo, that is subjects acted as their own control in a cross-over trial whereas Fuller et al (1995) employed a parallel design. Given the inter-and intra-individual variation in LDL oxidation (Gatto & Samman, 1995) data from the same individual before and after treatment is likely to be more reliable than comparisons between a treatment vs a control group.
The results of a recent study have shown that, after adjustment for the recognised major risk factors, increasing vitamin C from food plus supplements is associated with an increased risk of death from CHD in post menopausal women (Relative Risk 1.49 for the highest quintile of intake [b 391 mg/d]; P`0.02 for trend). However, when the data is re-analysed to investigate the effect of AA from either food or supplements alone, the relationship was no longer observed (Kushi et al, 1996) . Similar observations were reported in other epidemiological studies (Rimm et al, 1993; . High doses of AA are postulated to be undesirable because of the increased bioavailability of iron, particularly in groups who are not at risk of anaemia, and because of the potential action of AA to act as a pro-oxidant (Herbert, 1993) . In contrast to the effect on dietary iron, large quantities of AA fed to rats have been shown to reduce copper status (van den Berg et al, 1990 ) and as such may result in reduced activities of copper-dependent enzymes. In a pilot study published in abstract form (Hallen et al, 1994) , we have shown that healthy women who are supplemented with 1 g AA per day for four weeks have a signi®cant reduction in the activity of superoxide dismutase, a key enzyme in the antioxidant integrated system.
The effects of AA on CHD may display a seasonal effect. In a recent study in a group of elderly subjects AA had no effect on the risk of CHD (Gale et al, 1985) . However, when seasonal effects are considered, it was found that increasing AA intake by modest quantities for example one orange per day, appeared to protect against the rise in the incidence of CHD during the winter season, through an effect on haemostatic variables (Khaw and Woodhouse, 1995) . The reported seasonal effects point to the possibility of confounders in the relationship between AA and CHD. Foods rich in AA are often sources of other antioxidants which are either recognised nutrients, such as b-carotene, or non-nutrients, such as avonoids. The latter are being studied increasingly because of their potential roles in the prevention of the major chronic diseases (Cook & Samman, 1996; Samman et al, 1996) . The epidemiological reports pointing to a negative correlation between plasma AA and CHD may be confounded by the presence of unidenti®ed factors and under those circumstances plasma AA is behaving as a surrogate biomarker (Ness et al, 1996) . These observations do not support the use of large dose AA supplements in order to reduce the risk of CHD but concur with recommendations to eat a variety of foods and an abundance of fruits and vegetables.
